FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

wasinigton,	D.C.	20343	

Washington, D.C. 20049	OMB APPROVAL		
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP	OMB Number:	3235-0	

VNERSHIP	OWID 7 II 1	ONB/IITROVAL								
	OMB Number:	3235-0287								
	Estimated average	Estimated average burden								
	hours per response	: 0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Fernandes Peter				2. Issuer Name and Ticker or Trading Symbol Bellerophon Therapeutics, Inc. [BLPH]							(Che	lationship of ck all applica Director	able)	g Perso	on(s) to Issu 10% Ov Other (s	vner		
(Last) (First) (Middle) C/O BELLEROPHON THERAPEUTICS, INC. 184 LIBERTY CORNER ROAD, SUITE 302				0	3. Date of Earliest Transaction (Month/Day/Year) 01/12/2018								X Officer (give title below) Other (steel) Chief Regulatory & Safety Of				fr	
(Street) WARREN NJ 07059 (City) (State) (Zip)				4.	4. If Amendment, Date of Original Filed (Month/Day/Year)					6. Inc Line)	′							
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
1. Title of Security (Instr. 3)		2. ¹ Da	2. Transaction Date (Month/Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Year)		3. 4. Securi Transaction Disposed Code (Instr. 5)		ities Acquired (A) d d Of (D) (Instr. 3, 4		or	5. Amoun Securities Beneficial Owned Fo	s lly ollowing	Form:	: Direct Indirect str. 4)	7. Nature of Indirect Beneficial Ownership		
								Code	v	Amount	(A) (D)	or P	rice	Reported Transaction (Instr. 3 and	on(s)			(Instr. 4)
Common Stock			0	1/12/20	2/2018		A		31,527 A			\$ <mark>0</mark>	113,980			D		
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																	
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		Derivative		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amour of Securities Underlying Derivative Security (Instr. 3 and 4)			8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported	e s ally	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	v	(A)		Date Exercisable		xpiration ate	Title	Amo or Num of S			Transaction(s) (Instr. 4)		<u>'</u>	
Stock Option (right to buy)	\$2.03	01/12/2018		A		100,000		(1)	0:	1/12/2028	Common Stock	100	,000	\$0	100,00	00	D	

Explanation of Responses:

 $1.\ This\ option\ was\ granted\ on\ January\ 12,\ 2018.\ This\ option\ vests\ in\ quarterly\ installments\ over\ a\ four-year\ period\ from\ the\ date\ of\ grant.$

Remarks:

/s/ Peter Fernandes

01/17/2018

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.